Tafamidis (Vyndaqel®). HTA ID: 20017

Assessment Status Assessment process complete
HTA ID 20017
Drug Tafamidis
Brand Vyndaqel®
Indication For the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy.
Assessment Process
Rapid review commissioned 30/03/2020
Rapid review completed 07/04/2020
Rapid review outcome A full HTA is recommended to assess the clinical and cost effectiveness of tafamidis compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 29/04/2020
Pre-submission consultation with Applicant 18/05/2020
Full submission received from Applicant 01/07/2020
Preliminary review sent to Applicant 18/08/2020
NCPE assessment re-commenced 10/09/2020
Factual accuracy sent to Applicant 11/09/2020
NCPE assessment re-commenced 18/09/2020
NCPE assessment completed 25/09/2020
NCPE assessment outcome The NCPE recommends that tafamidis not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

Plain English Summary

The HSE has approved reimbursement following confidential price negotiations March 2022.